Daniel GoldmanSell
ARWR · Transaction Jan 31, 2023 · Filed Feb 24, 2023 · $1,001 to $15,000
XNAS · ARWR
-1.09% · -$0.7400 · Vol 4.0M
Market closed · last close 4:00 PM ET · price as of 19:09:43 ET
Arrowhead Research Corporation
PHARMACEUTICAL PREPARATIONS
$67.00
Follow $ARWR
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $ARWR by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredFri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET · ARWR
MethodologyARWR
Arrowhead Research Corporation
Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Lower range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
39/ 100
Veridion Score
Lower range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is ARWR moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Arrowhead Research Corporation
PHARMACEUTICAL PREPARATIONSListed since
1995
Employees
711
Country
US
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$67.83
Day high
$68.05
Day low
$66.36
Previous close
$67.74
52W high
$89.59
-25.21% from high
52W low
$31.66
61% of range
Market cap
$9.4B
EPS
$-3.3300
Beta
1.29
Shares out
141.3M
Volume
4M
2.49× rel vol
Avg volume
1.6M
VWAP
$66.71
Price history computed in-house
1W
-19.13%
1M
-23.09%
3M
-18.29%
1Y
+118.31%
YTD
+0.92%
SMA 50 $82.73 · below
SMA 200 $72.48 · below
52W position 61%
ARWR overview
Related filings and maps
Public disclosures
Congress activity in ARWR
Official filing ↗
Arrowhead Pharmaceuticals, Inc. · Transaction Jan 31, 2023 · Filed Feb 24, 2023 · $1,001 to $15,000
Federal contracts
ARWR contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ARWR in this window.
Lobbying spend
ARWR lobbying filings, year to date.
Registered lobbying filings matched to Arrowhead Research Corporation.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ARWR in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for ARWR.
Options
Sovereign unlock shows live options positioning for ARWR.